Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123050 | 0.87 | GABRA1 (0.42) | ADORA2AADORA1NOTUMNPC1RAB9A | |
| SCHEMBL17122197 | 0.85 | PDE4B (0.46) | ADORA2AADORA1NOTUMNPC1RAB9A | |
| SCHEMBL8564692 | 0.84 | PTGS1 (0.43) | ADORA2AADORA1NOTUMNPC1RAB9A | |
| SCHEMBL6122412 | 0.84 | GABRA1 (0.49) | ADORA2AADORA1NOTUMSMN1; SMN2TP53 | |
| SCHEMBL8564100 | 0.80 | NPY5R (0.40) | ADORA2AADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3506902 | 0.77 | PDE4B (0.57) | NOTUMNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6122151 | 0.72 | GABRA1 (0.40) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL6122545 | 0.72 | GABRG2 (0.58) | SMN1; SMN2TP53ALDH1A1GABRA1GABRG2 | |
| SCHEMBL6122430 | 0.72 | GABRA1 (0.39) | NOTUMNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6121774 | 0.72 | GABRA1 (0.39) | ADORA2ANOTUMALDH1A1MAPTPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801879-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801879-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3034079-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2640391-B1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9145372-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145372-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014153180-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GALLAGHER MICHELA (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014078377-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | AGENEBIO, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068161-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | ADORA2A 70/4885ADORA1 182/4885NOTUM 4407/4885 |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | ADORA2A 70/4885ADORA1 182/4885NOTUM 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.